Beacon Investment Advisory Services Inc. Has $26 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Beacon Investment Advisory Services Inc. increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 0.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 302,233 shares of the company’s stock after purchasing an additional 641 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Novo Nordisk A/S were worth $25,998,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in NVO. Natixis Advisors LLC grew its position in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC boosted its position in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares during the last quarter. Talbot Financial LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $4,066,000. Versant Capital Management Inc acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $86,000. Finally, Zions Bancorporation N.A. increased its position in Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after purchasing an additional 6,726 shares during the period. 11.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Stock Down 0.5 %

Shares of NVO stock opened at $80.59 on Thursday. The company has a market capitalization of $361.65 billion, a price-to-earnings ratio of 26.08, a P/E/G ratio of 0.89 and a beta of 0.45. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The firm has a fifty day moving average of $96.10 and a 200-day moving average of $115.79. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.